Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis

International Journal of Rheumatic Diseases

Volumn 18, Issue 4, 2015, Pages 476-479

  Fujita, Shunichi ^a   Kosaka, Nami ^a   Mito, Takafumi ^a   Hayashi, Hiroaki ^a   Morita, Yoshitaka ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 6; MEDRONATE TECHNETIUM TC 99M; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; SERUM AMYLOID A; TOCILIZUMAB; MONOCLONAL ANTIBODY;

AGED; AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; ASEPTIC SKIN ABSCESS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; ERYTHROCYTE COUNT; HEMODIALYSIS; HUMAN; JOINT SWELLING; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SAPHO SYNDROME; SKIN ABSCESS; SKIN BIOPSY; STERNOCLAVICULAR JOINT; STOMACH BIOPSY; THORAX PAIN; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ABSCESS; ACQUIRED HYPEROSTOSIS SYNDROME; COMPLICATION; DISEASE COURSE; FOLLOW UP; METABOLISM; PATHOPHYSIOLOGY; RARE DISEASE; RENAL INSUFFICIENCY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; TREATMENT OUTCOME;

ABSCESS; ACQUIRED HYPEROSTOSIS SYNDROME; AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; RARE DISEASES; RENAL INSUFFICIENCY; RISK ASSESSMENT; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84929711200     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12525     Document Type: Article

References (10)

1. Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37, 1699-704.
2. Miyagawa I, Nakayamada S, Saito K et al. (2014) Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol 24, 405-9.
3. Redondo-Pachón MD, Enríquez R, Sirvent AE et al. (2013) Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease. Ren Fail 35, 547-50.
4. Kosaka N, Hayashi H, Mito T et al. (2013) Predominance of Th2 and regulatory cytokines in the serum of a patient with IgG4-related lymphadenopathy. Int J Rheum Dis 16, 486-8.
5. Li KJ, Yu CL, Lin WC, Lu MC, Wu CH, Hsieh SC (2006) Concomitant aseptic subcutaneous abscess and immunoglobulin M nephropathy - rare extraintestinal manifestations in ulcerative colitis. Dig Dis Sci 51, 401-5.
6. Hara H, Wakui F, Fujitsuka A, Ochiai T, Morishima T (2000) Subcutaneous abscesses in a patient with ulcerative colitis. J Am Acad Dermatol 42, 363-5.
7. Murata I, Satoh K, Yoshikawa I, Masumoto A, Sasaki E, Otsuki M (1999) Recurrent subcutaneous abscess of the sternal region in ulcerative colitis. Am J Gastroenterol 94, 844-5.
8. Sakurai A, Teraki Y (2012) TNF inhibitor in the treatment of a severe case of palmoplantar pustulosis. J Visual Dermatol 11, 1080-1 (in Japanese).
9. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-64.
10. Bannai E, Yamashita H, Kaneko S et al. (2014) Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol (PMID: 24697199) (in press).